Although GLP-1 agonists have potential as a therapeutic alternative for obesity in children and adolescents, their use remains exploratory, necessitating more research to ascertain their long-term safety and effectiveness in pediatric cohorts. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.